Table 2 Distribution of clinical pathological variables among 78 1p-intact neuroblastoma cases with and without mutational variants
Variable | Neuroblastoma candidate gene variant present (n (%)) | Neuroblastoma candidate genes variant absent (n (%)) | Chi-square | P-value | |
|---|---|---|---|---|---|
Gender (n = 78) | Male | 26 (57.8) | 18 (54.5) | 0.081 | 0.776 |
Female | 19 (42.2) | 15 (45.5) | |||
INPC histology (n = 78) | FH | 18 (40.0) | 19 (57.6) | 2.359 | 0.125 |
UH | 27 (60.0) | 14 (42.4) | |||
Treatment status (n = 78) | Pre-chemotherapy | 4 (8.9) | 5 (15.2) | 0.732 | 0.392 |
Post-chemotherapy/ relapse | 41 (91.1) | 28 (84.8) | |||
Specimen site (n = 78) | Primary tumor | 40 (88.9) | 32 (97.0) | 5.165 | 0.076 |
Metastatic tumor | 5 (11.1) | - | |||
Both | - | 1 (3.0) | |||
MYCN status (n = 78) | Amplified | 9 (20.0) | 6 (18.2) | 0.041 | 0.840 |
Non-amplified | 36 (80.0) | 27 (81.8) | |||
11q status (n = 76) | Deleted | 7 (36.8) | 12 (21.1) | 4.017 | 0.045 |
Not deleted | 12 (63.2) | 45 (78.9) | |||
Metastatic status (n = 76) | Metastatic | 34 (75.6) | 19 (61.3) | 1.770 | 0.183 |
Localized | 11 (24.4) | 12 (38.7) | |||
COG risk (n = 75) | High | 40 (88.9) | 22 (73.3) | 3.040 | 0.081 |
Low/intermediate | 5 (11.1) | 8 (26.7) | |||